This report focuses on opportunities for international
pharmaceutical companies to make real estate an integral feature in the value chain with a special focus on how Poland is proving to be one of the most popular locations for the industry.
Global pharma is undergoing an economic and technical revolution.
M&A activity is run in parallel with a quest for innovation and market coverage. Increasingly the global players are having to establish a tiered market footprint where market price is a critical driver. Companies are pursuing R&D, generic and
OTC models. In pursuit of this strategy pharma companies are adapting their business processes to suit a more complex global environment. Today’s locations of research, development, manufacturing and distribution are not necessary those of tomorrow. “In house” today may well become outsourced tomorrow as markets and mergers force efficiencies on a thus far inward focused and self-contained industry. The strive for efficiency intensifies the need to actively manage real estate portfolios. Poland with its intellectual, labour and property market potential looks set to play an important role in rationalization strategies of many of the pharmaceutical companies.
